Undergraduate Degree

  • New College , 1997 , Sarasota , FL

Medical School

  • University of Florida , 2006 , Gainesville , FL


  • Shands Teaching Hospital/ University of Florida , 2007 , Gainesville , FL

Graduate Degree

  • University of Florida , 2012 , Gainesville , FL


  • Shands Teaching Hospital/ University of Florida , 2015 , Gainesville , FL


  • Boston Children's Hospital , 2017 , Boston , MA


  • Massachusetts General Hospital , 2019 , Boston , MA


Dr. Cuenca completed his medical school, graduate school, and residency at the University of Florida in Gainesville, Fl. During his research hiatus in residency, he obtained a PhD examining the role of innate immunity and toll-like receptor signaling in neonatal sepsis. He then went on to complete a fellowship in Pediatric Surgery at Boston Children’s Hospital. Due to his interest in pediatric hepatobiliary disease and transplant medicine, he went on to complete a fellowship in Transplant Surgery at Massachusetts General Hospital. He is clinically interested in pediatric hepatobiliary and pancreatic disease, solid organ transplantation, mid-aortic vascular disease, and other general surgical conditions of children. His research efforts are focused on examining the role of innate immunity in allograft tolerance, as well as novel efforts to expand the utility of normothermic machine perfusion for use in solid organ transplantation.


  • American Board of Surgery, General Surgery
  • American Board of Surgery, Pediatric Surgery


Publications powered by Harvard Catalyst Profiles

  1. Short Bowel Syndrome and Kidney Transplantation: Challenges, Outcomes, and the Use of Teduglutide. Case Rep Transplant. 2020; 2020:8819345. View abstract
  2. Resolution of a High Grade and Metastatic BK Polyomavirus-Associated Urothelial Cell Carcinoma Following Radical Allograft Nephroureterectomy and Immune Checkpoint Treatment: A Case Report. Transplant Proc. 2020 Nov; 52(9):2720-2725. View abstract
  3. Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning. Am J Transplant. 2020 06; 20(6):1619-1628. View abstract
  4. Pediatric liver transplant following near catastrophic head bleed: Lessons learned. Pediatr Transplant. 2020 03; 24(2):e13646. View abstract
  5. Giant Gastroschisis with Complete Liver Herniation: A Case Report of Two Patients. Case Rep Surg. 2019; 2019:4136214. View abstract
  6. Pediatric liver transplantation. Semin Pediatr Surg. 2017 Aug; 26(4):217-223. View abstract
  7. Clostridium difficile Infections after Blunt Trauma: A Different Patient Population? Surg Infect (Larchmt). 2015 Aug; 16(4):421-7. View abstract
  8. Improved emergency myelopoiesis and survival in neonatal sepsis by caspase-1/11 ablation. Immunology. 2015 Jun; 145(2):300-11. View abstract
  9. Successful implementation of a packed red blood cell and fresh frozen plasma transfusion protocol in the surgical intensive care unit. PLoS One. 2015; 10(5):e0126895. View abstract
  10. TRIF-dependent innate immune activation is critical for survival to neonatal gram-negative sepsis. J Immunol. 2015 Feb 01; 194(3):1169-77. View abstract
  11. Delayed emergency myelopoiesis following polymicrobial sepsis in neonates. Innate Immun. 2015 May; 21(4):386-91. View abstract
  12. Omental flaps for coverage of sacral or gluteal defects: a useful and potentially underused tool. Am Surg. 2014 Jul; 80(7):e202-4. View abstract
  13. A better understanding of why murine models of trauma do not recapitulate the human syndrome. Crit Care Med. 2014 Jun; 42(6):1406-13. View abstract
  14. Novel role for tumor-induced expansion of myeloid-derived cells in cancer cachexia. J Immunol. 2014 Jun 15; 192(12):6111-9. View abstract
  15. Host responses to sepsis vary in different low-lethality murine models. PLoS One. 2014; 9(5):e94404. View abstract
  16. Protective immunity and defects in the neonatal and elderly immune response to sepsis. J Immunol. 2014 Apr 01; 192(7):3156-65. View abstract
  17. Persistent inflammation, immunosuppression, and catabolism syndrome after severe blunt trauma. J Trauma Acute Care Surg. 2014 Jan; 76(1):21-9; discussion 29-30. View abstract
  18. Aged mice are unable to mount an effective myeloid response to sepsis. J Immunol. 2014 Jan 15; 192(2):612-22. View abstract
  19. Is there value in plasma cytokine measurements in patients with severe trauma and sepsis? Methods. 2013 May 15; 61(1):3-9. View abstract
  20. Development of a genomic metric that can be rapidly used to predict clinical outcome in severely injured trauma patients. Crit Care Med. 2013 May; 41(5):1175-85. View abstract
  21. Acute kidney injury is associated with early cytokine changes after trauma. J Trauma Acute Care Surg. 2013 Apr; 74(4):1005-13. View abstract
  22. Identification and description of a novel murine model for polytrauma and shock. Crit Care Med. 2013 Apr; 41(4):1075-85. View abstract
  23. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2013 Feb 26; 110(9):3507-12. View abstract
  24. Role of innate immunity in neonatal infection. Am J Perinatol. 2013 Feb; 30(2):105-12. View abstract
  25. A genomic analysis of Clostridium difficile infections in blunt trauma patients. J Trauma Acute Care Surg. 2013 Jan; 74(1):334-8. View abstract
  26. Soybean oil: a potentially new intravascular perfusate. Perfusion. 2013 Mar; 28(2):160-6. View abstract
  27. The acute immunological response to blood transfusion is influenced by polymicrobial sepsis. Shock. 2012 Dec; 38(6):598-606. View abstract
  28. Pediatric pancreatic trauma: trending toward nonoperative management? Am Surg. 2012 Nov; 78(11):1204-10. View abstract
  29. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg. 2012 Jun; 72(6):1491-501. View abstract
  30. Myeloid-derived suppressor cells in sepsis: friend or foe? Intensive Care Med. 2012 Jun; 38(6):928-30. View abstract
  31. Benchmarking outcomes in the critically injured trauma patient and the effect of implementing standard operating procedures. Ann Surg. 2012 May; 255(5):993-9. View abstract
  32. "Pulling the plug"--management of meconium plug syndrome in neonates. J Surg Res. 2012 Jun 15; 175(2):e43-6. View abstract
  33. Obese patients show a depressed cytokine profile following severe blunt injury. Shock. 2012 Mar; 37(3):253-6. View abstract
  34. A genomic storm in critically injured humans. J Exp Med. 2011 Dec 19; 208(13):2581-90. View abstract
  35. Microfluidics-based capture of human neutrophils for expression analysis in blood and bronchoalveolar lavage. Lab Invest. 2011 Dec; 91(12):1787-95. View abstract
  36. The Glue Grant experience: characterizing the post injury genomic response. Eur J Trauma Emerg Surg. 2011 Dec; 37(6):549-58. View abstract
  37. B cells enhance early innate immune responses during bacterial sepsis. J Exp Med. 2011 Aug 01; 208(8):1673-82. View abstract
  38. Neutrophil mobilization from the bone marrow during polymicrobial sepsis is dependent on CXCL12 signaling. J Immunol. 2011 Jul 15; 187(2):911-8. View abstract
  39. Critical role for CXC ligand 10/CXC receptor 3 signaling in the murine neonatal response to sepsis. Infect Immun. 2011 Jul; 79(7):2746-54. View abstract
  40. The usefulness of the upper gastrointestinal series in the pediatric patient before anti-reflux procedure or gastrostomy tube placement. J Surg Res. 2011 Oct; 170(2):247-52. View abstract
  41. Sepsis induces early alterations in innate immunity that impact mortality to secondary infection. J Immunol. 2011 Jan 01; 186(1):195-202. View abstract
  42. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol Med. 2011 Mar-Apr; 17(3-4):281-92. View abstract
  43. Cecal ligation and puncture. Curr Protoc Immunol. 2010 Nov; Chapter 19:Unit 19.13. View abstract
  44. Do Tregs link sepsis to tumor growth? Blood. 2010 Jun 03; 115(22):4324-5. View abstract
  45. Cutting edge: bacterial infection induces hematopoietic stem and progenitor cell expansion in the absence of TLR signaling. J Immunol. 2010 Mar 01; 184(5):2247-51. View abstract
  46. Type I interferon signaling in hematopoietic cells is required for survival in mouse polymicrobial sepsis by regulating CXCL10. J Exp Med. 2010 Feb 15; 207(2):319-26. View abstract
  47. Diminishing role of contrast enema in simple meconium ileus. J Pediatr Surg. 2009 Nov; 44(11):2130-2. View abstract
  48. Equestrian injuries in children. J Pediatr Surg. 2009 Jan; 44(1):148-50. View abstract
  49. Pulmonary surgery in cystic fibrosis. Semin Pediatr Surg. 2008 Feb; 17(1):60-5. View abstract
  50. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer. 2006 Aug 01; 107(3):459-66. View abstract
  51. In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood. 2006 Apr 01; 107(7):2871-8. View abstract
  52. Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood. 2005 Feb 01; 105(3):1135-43. View abstract
  53. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res. 2003 Dec 15; 63(24):9007-15. View abstract
  54. A critical role for Stat3 signaling in immune tolerance. Immunity. 2003 Sep; 19(3):425-36. View abstract
  55. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood. 2001 Aug 15; 98(4):1070-7. View abstract
  56. Pancreas transplant graft evaluation using the MIBI scan--a useful tool. Transplant Proc. 1998 Mar; 30(2):257-60. View abstract